Insulin-Like Growth Factor-1 Sustains Stem Cell–Mediated Renal Repair

Imberti, Barbara; Morigi, Marina; Tomasoni, Susanna; Rota, Cinzia; Corna, Daniela; Longaretti, Lorena; Rottoli, Daniela; Valsecchi, Federica; Benigni, Ariela; Wang, Jun; Abbate, Mauro; Zoja, Carla; Remuzzi, Giuseppe

doi:10.1681/asn.2006121318

Cited by 286 publications

(264 citation statements)

References 49 publications

Supporting

Mentioning

245

Contrasting

Unclassified

Order By: Relevance

“…The contribution of MSC to increasing proliferation and/or reducing apoptosis for organ rescue has been broadly shown in vivo for renal epithelial cells 19 and nerve cells 20 as a therapeutic benefit. Moreover, some results obtained in vitro show similar effects of MSC on the regulation of apoptosis and/or proliferation of renal epithelial cells, 21 endothelial cells such as aortic cells, 22 brain microvascular cells 23 and cardiomyocytes. 24 Finally, convincing in vitro results obtained by Parekkadan et al 25 show, on the contrary, that MSC favor the death and reduce the proliferation of resident liver cells, specifically activated stellate cells.…”

Section: Discussionmentioning

confidence: 73%

Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis

et al. 2009

View full text Add to dashboard Cite

Patients who undergo pelvic or abdominal radiotherapy may develop acute and/or chronic side effects resulting from gastrointestinal tract (GIT) alterations. In this study, we address the question of the regenerative capability of mesenchymal stem cells (MSC) after radiation-induced GIT injury. We also propose cellular targets of MSC therapy. We report that the infusion of human bone marrow-derived MSC (hMSC) provides a therapeutic benefit to NOD/SCID mice undergoing radiation-induced GIT failure. We observed that hMSC treatment brings about fast recovery of the small intestine (structure and function) in mice with reversible alterations and extends the life of mice with irreversible GIT disorders. The effects of hMSC are a consequence of their ability to improve the renewal capability of small intestinal epithelium. hMSC treatment favors the re-establishment of cellular homeostasis by both increasing endogenous proliferation processes (Ki67 immunostaining) and inhibiting apoptosis (TUNEL staining) of radiation-induced small intestinal epithelial cells. Our results suggest that MSC infusion may be used as a therapeutic treatment to limit radiation-induced GIT damage.

show abstract

Section: Discussionmentioning

confidence: 73%

Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…59 In another study it was shown that the renoprotective effect of MSCs was mediated by the mitogenic and pro-survival insulin growth factor-1 (IGF-1) produced by the MSCs. 60 Recently, a vasculotropic effect of infused MSC in the kidney was shown, 61 which may be relevant to SSc.…”

Section: Animal Models Of Tissue Protectionmentioning

confidence: 99%

Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks

Tyndall

Uccelli

2009

Bone Marrow Transplant

107

View full text Add to dashboard Cite

“…MSCs have been shown to secrete a number of growth factors [41]. Imberti et al [43] suggest that this humoral function results from IGF1, whereas Bi et al [42] attributed it to a combination of HGF, IGF1 and EGF. A recent paper by Togel et al [44] suggests that VEGF is the critical factor in the renoprotection afforded by MSCs.…”

Section: Mesenchymal Stromal Cells (Mscs)mentioning

confidence: 99%

Stem cell options for kidney disease

Hopkins

Rae

et al. 2008

The Journal of Pathology

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is increasing at the rate of 6-8% per annum in the US alone. At present, dialysis and transplantation remain the only treatment options. However, there is hope that stem cells and regenerative medicine may provide additional regenerative options for kidney disease. Such new treatments might involve induction of repair using endogenous or exogenous stem cells or the reprogramming of the organ to reinitiate development. This review addresses the current state of understanding with respect to the ability of non-renal stem cell sources to influence renal repair, the existence of endogenous renal stem cells and the biology of normal renal repair in response to damage. Understanding repair options via an understanding of renal developmentThe prevalence and incidence of chronic kidney disease (CKD) is increasing at 6-8% per annum in the USA alone, largely as a result of increased prevalence of diabetes and obesity [1]. To understand what might be possible with respect to cellular therapies or regenerative medicine for the kidney, one first needs to consider what is understood about normal renal development and response to injury. The kidney has been classically regarded as an organ with minimal cellular turnover and no capacity for regeneration. The subsequent identification of stem cells in a number of such organs, including the brain, has challenged this view. However, the dogma remains that the kidney reaches a maximal complement of nephrons and then loses these over time [2]. This dogma is drawn from our understanding of the development of this organ. The progenitor population during developmentThe kidney is mesodermal in origin and develops from two populations derived from intermediate mesoderm, the ureteric bud (UB) and the metanephric mesenchyme (MM). While an even broader potential had been proposed [3], genetic and lineage analyses have confirmed that the MM gives rise to all portions of the nephron other than the collecting ducts and also gives rise to elements of the renal interstitium [4][5][6]. The UB gives rise to the ureter and collecting ducts only. The MM is apparently not homogeneous but forms condensed mesenchyme around the tips of the branching UB. This cap mesenchyme (CM) contains self-renewing progenitors capable of generating all cells of the nephron other than the collecting ducts via an initial mesenchyme-epithelial transition (MET) event throughout the prenatal developmental period [6]. The continued expression of the transcription factor Six2 in CM is required for maintenance of this stem cell population during kidney development [5]. As the UB branches and extends through the MM, individual MET events occur at the underside of each tip to form a new nephron [2]. This nephron endowment therefore proceeds from the centre of the kidney out to the periphery, with the CM stem cell field remaining on the outer edge of the expanding organ. Endowment of new nephrons is restricted to prenatal development in humans, while in rodents it persists only until the imm...

show abstract

Insulin-Like Growth Factor-1 Sustains Stem Cell–Mediated Renal Repair

Cited by 286 publications

References 49 publications

Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis

Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis

Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks

Stem cell options for kidney disease

Contact Info

Product

Resources

About